Literature DB >> 22846735

Genetic testing by cancer site: uterus.

Molly S Daniels1.   

Abstract

This review article discusses hereditary cancer predisposition syndromes with uterine manifestations. Lynch syndrome accounts for 2% to 3% of endometrial cancers. The identification of endometrial cancer patients at risk for Lynch syndrome is discussed, as are the characteristics of Lynch syndrome-associated endometrial cancer and the screening and prevention options for women at risk for Lynch syndrome-associated endometrial cancer. Endometrial cancer associated with PTEN hamartoma tumor syndrome (also known as Cowden syndrome) is also discussed. HLRCC (hereditary leiomyomatosis and renal cell carcinoma), which has an associated high risk of symptomatic uterine leiomyomas, is reviewed.

Entities:  

Mesh:

Year:  2012        PMID: 22846735     DOI: 10.1097/PPO.0b013e3182610cc2

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  7 in total

Review 1.  The mutational landscape of endometrial cancer.

Authors:  Bo Hong; Matthieu Le Gallo; Daphne W Bell
Journal:  Curr Opin Genet Dev       Date:  2015-01-23       Impact factor: 5.578

2.  Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.

Authors:  Amy S Joehlin-Price; Carmen M Perrino; Julie Stephens; Floor J Backes; Paul J Goodfellow; David E Cohn; Adrian A Suarez
Journal:  Gynecol Oncol       Date:  2014-01-17       Impact factor: 5.482

3.  Vascular marker expression during the development of various types of gynaecological malignancy.

Authors:  Peter Urban; Miroslava Bilecova Rabajdova; Jan Varga; Peter Kruzliak; Viera Fialkovicova; Eva Durovcova; Maria Marekova
Journal:  Tumour Biol       Date:  2014-08-12

4.  Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Authors:  Kassondra S Grzankowski; J Brian Szender; Chandra L Spring-Robinson; Shashikant B Lele; Kunle O Odunsi; Peter J Frederick
Journal:  Int J Gynecol Cancer       Date:  2016-10       Impact factor: 3.437

Review 5.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

6.  Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives.

Authors:  Alison Stewart
Journal:  PLoS Curr       Date:  2013-09-16

7.  Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Authors:  Günter Emons; Eric Steiner; Dirk Vordermark; Christoph Uleer; Nina Bock; Kerstin Paradies; Olaf Ortmann; Stefan Aretz; Peter Mallmann; Christian Kurzeder; Volker Hagen; Birgitt van Oorschot; Stefan Höcht; Petra Feyer; Gerlinde Egerer; Michael Friedrich; Wolfgang Cremer; Franz-Josef Prott; Lars-Christian Horn; Heinrich Prömpeler; Jan Langrehr; Steffen Leinung; Matthias W Beckmann; Rainer Kimmig; Anne Letsch; Michael Reinhardt; Bernd Alt-Epping; Ludwig Kiesel; Jan Menke; Marion Gebhardt; Verena Steinke-Lange; Nils Rahner; Werner Lichtenegger; Alain Zeimet; Volker Hanf; Joachim Weis; Michael Mueller; Ulla Henscher; Rita K Schmutzler; Alfons Meindl; Felix Hilpert; Joan Elisabeth Panke; Vratislav Strnad; Christiane Niehues; Timm Dauelsberg; Peter Niehoff; Doris Mayr; Dieter Grab; Michael Kreißl; Ralf Witteler; Annemarie Schorsch; Alexander Mustea; Edgar Petru; Jutta Hübner; Anne Derke Rose; Edward Wight; Reina Tholen; Gerd J Bauerschmitz; Markus Fleisch; Ingolf Juhasz-Boess; Lax Sigurd; Ingo Runnebaum; Clemens Tempfer; Monika J Nothacker; Susanne Blödt; Markus Follmann; Thomas Langer; Heike Raatz; Simone Wesselmann; Saskia Erdogan
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-10-19       Impact factor: 2.915

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.